226 related articles for article (PubMed ID: 34214700)
1. Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.
Boehnke KF; Gagnier JJ; Matallana L; Williams DA
J Pain; 2022 Jan; 23(1):45-54. PubMed ID: 34214700
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey.
Boehnke KF; Gagnier JJ; Matallana L; Williams DA
J Pain; 2021 May; 22(5):556-566. PubMed ID: 33400996
[TBL] [Abstract][Full Text] [Related]
3. Substituting Cannabidiol for Opioids and Pain Medications Among Individuals With Fibromyalgia: A Large Online Survey.
Boehnke KF; Gagnier JJ; Matallana L; Williams DA
J Pain; 2021 Nov; 22(11):1418-1428. PubMed ID: 33992787
[TBL] [Abstract][Full Text] [Related]
4. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
5. Cannabis Use Preferences and Decision-making Among a Cross-sectional Cohort of Medical Cannabis Patients with Chronic Pain.
Boehnke KF; Scott JR; Litinas E; Sisley S; Clauw DJ; Goesling J; Williams DA
J Pain; 2019 Nov; 20(11):1362-1372. PubMed ID: 31132510
[TBL] [Abstract][Full Text] [Related]
6. Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia.
Berger AA; Keefe J; Winnick A; Gilbert E; Eskander JP; Yazdi C; Kaye AD; Viswanath O; Urits I
Best Pract Res Clin Anaesthesiol; 2020 Sep; 34(3):617-631. PubMed ID: 33004171
[TBL] [Abstract][Full Text] [Related]
7. Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021.
Geppert J; Lietzow J; Hessel-Pras S; Kirsch F; Schäfer B; Sachse B
BMC Public Health; 2023 Nov; 23(1):2318. PubMed ID: 37996800
[TBL] [Abstract][Full Text] [Related]
8. CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.
Wheeler M; Merten JW; Gordon BT; Hamadi H
Subst Use Misuse; 2020; 55(7):1138-1145. PubMed ID: 32093530
[No Abstract] [Full Text] [Related]
9. Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles.
Fedorova EV; Wong CF; Ataiants J; Iverson E; Conn BM; Lankenau SE
Drug Alcohol Depend; 2021 Apr; 221():108648. PubMed ID: 33676073
[TBL] [Abstract][Full Text] [Related]
10. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia.
van de Donk T; Niesters M; Kowal MA; Olofsen E; Dahan A; van Velzen M
Pain; 2019 Apr; 160(4):860-869. PubMed ID: 30585986
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Dispensing and Utilization Patterns of Medical Cannabis Products in State Licensed Cannabis Dispensaries.
Tanco K; Olson A; Fellman B; Jankowski M; Lai SY; Shete S; Harbison K; Scheid J; Bruera E
J Palliat Med; 2023 Nov; 26(11):1482-1487. PubMed ID: 37285183
[No Abstract] [Full Text] [Related]
12. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
Miller OS; Elder EJ; Jones KJ; Gidal BE
Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
[TBL] [Abstract][Full Text] [Related]
13. Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population.
Highet BH; Lesser ER; Johnson PW; Kaur JS
Am J Hosp Palliat Care; 2020 Aug; 37(8):589-593. PubMed ID: 31986898
[TBL] [Abstract][Full Text] [Related]
14. Use and Perceptions of Cannabidiol Products in Canada and in the United States.
Goodman S; Wadsworth E; Schauer G; Hammond D
Cannabis Cannabinoid Res; 2022 Jun; 7(3):355-364. PubMed ID: 33998872
[No Abstract] [Full Text] [Related]
15. Patterns and correlates of cannabidiol product and marijuana co-use in a sample of U.S. young adults.
Dunbar MS; Seelam R; Tucker JS; Firth CL; Pedersen ER; Klein DJ; Rodriguez A; D'Amico EJ
Addict Behav; 2022 Mar; 126():107185. PubMed ID: 34839070
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores.
Spindle TR; Sholler DJ; Cone EJ; Murphy TP; ElSohly M; Winecker RE; Flegel RR; Bonn-Miller MO; Vandrey R
JAMA Netw Open; 2022 Jul; 5(7):e2223019. PubMed ID: 35857320
[TBL] [Abstract][Full Text] [Related]
17. Selling cannabidiol products in Canada: A framing analysis of advertising claims by online retailers.
Zenone MA; Snyder J; Crooks V
BMC Public Health; 2021 Jul; 21(1):1285. PubMed ID: 34210299
[TBL] [Abstract][Full Text] [Related]
18. Cannabis in Parkinson's Disease: The Patients' View.
Yenilmez F; Fründt O; Hidding U; Buhmann C
J Parkinsons Dis; 2021; 11(1):309-321. PubMed ID: 33216043
[TBL] [Abstract][Full Text] [Related]
19. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses.
Lawn W; Freeman TP; Pope RA; Joye A; Harvey L; Hindocha C; Mokrysz C; Moss A; Wall MB; Bloomfield MA; Das RK; Morgan CJ; Nutt DJ; Curran HV
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3537-52. PubMed ID: 27585792
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol use in France in 2022: Results from a nationwide representative sample of adults.
Barré T; Lahaie E; Di Beo V; Carrieri P; Andler R; Nguyen-Thanh V; Beck F
Drug Alcohol Rev; 2024 Jul; 43(5):1294-1304. PubMed ID: 38561958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
